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INTRODUCTION 45
Multi-drug resistance (MDR) in Gram-negative pathogens, including the Enterobacteriaceae, 46
Pseudomonas aeruginosa, Acinetobacter spp., and Stenotrophomonas maltiphilia, poses a significant threat to the effective treatment of infections caused by these organisms (1) (2) (3) (4) . The control for each sample, the average CFU/ml values for treated samples were divided by those 133 from the same sample at 0 h (time = 0). Each experiment was repeated at least three times, 134 and a representative experiment is shown. 135 H33342 accumulation assay. The H33342 accumulation assay was used to evaluate the effect 136 of EPIs on the activity of the AcrAB-TolC efflux pump in several bacterial species essentially as 137 described (34) . Briefly, bacterial cultures were grown overnight in LB (Miller) with aeration at 37 138 °C and were used to inoculate fresh cultures (1:100 dilution) that were grown in LB (Miller) with 139 aeration until an optical density at 600 nm (OD 600 ) of 0.4-0.6 was reached. Bacterial cells were 140 harvested by centrifugation, and the cell pellet was washed with a volume of PBSM+G (PBS 141 containing 1 mM MgSO 4 and 20 mM glucose) equivalent to the original volume of the culture. 142
After centrifugation, the cell pellets were resuspended in PBSM+G and the OD 600 of each 143 suspension was adjusted to 0.2. Aliquots of 190 µl were transferred to the wells of a 96-well 144 assay plate (Costar 3515, Corning, NY; flat bottom, black plate). Various concentrations of test 145 compounds dissolved in DMSO or an equivalent volume of solvent alone were added to a total 146 of 8 assay wells (one column of wells) for each condition tested. The final concentration of 147 DMSO in all assays was 2%. The assay plates were incubated at 37 °C for 15 min, and 10 µl of 148 a solution of 50 µM H33342 in PBSM+G was added to each assay well, resulting in a final dye 149 concentration of 2.5 µM. Fluorescence (excitation and emission filter of 355 and 460 nm, 150 respectively) of each well was measured at 37 °C every 5 min for 30 min using a Victor 2 V 1420 151
Multilabel HTS Counter (Perkin Elmer, Waltham, MA). The average values and standard 152 deviations for the eight replicates for each condition were calculated using Microsoft Excel. 153
Each experiment was repeated at least three times, and a representative experiment is shown. 154
Kinetics of nitrocefin efflux by AcrAB-TolC in E. coli. The effects of EPIs on the kinetic 155 parameters of AcrAB-TolC in E. coli were estimated as described (35) . Briefly, HN1157 was 156 grown in modified LB broth, diluted 100-fold in the fresh medium, and incubated at 30 °C with 157 shaking until the OD600 reached 0.65. The cells were harvested, washed twice (50 mM 158 potassium phosphate buffer, pH 7.0, 5 mM MgCl 2 ), and resuspended in the same buffer at an 159 OD 600 of 0.8 (corresponding to 0.24 mg dry weight/mL). Nitrocefin was added at a desired final 160 concentration and the mixture incubated at 25 °C while OD 486 was measured over 30 min. The 161 concentration of nitrocefin in the periplasm (C p ) was calculated from the rate of hydrolysis by the 162 perplasmic β-lactamase (V h ) and the kinetic constants of the β-lactamase as described (35) . 163
The kinetic constants were derived by curve fitting of the velocity of AcrB (V e ) vs. C p values 164 using GraphPad Prism, version 5.04 (http://www.graphpad.com/) by using the Michaelis-Menten 165 equation. Each assay was repeated at least three times, and representative data are 166 presented. 167
Uptake of [3H]-TMG by the LacY permease. To estimate the effect of EPIs on the proton 168 motive force in E. coli HN1157, the accumulation of [3H]-TMG by the LacY permease was measured essentially as described (36) . Briefly, a culture of HN1157 was grown in LB medium 170 containing 1 mM of isopropyl β-D-1-thiogalactopyranoside (IPTG) at 30 º C with shaking, was 171 harvested at an OD 600 of ca. 0.65, and washed two times with 50 mM KHPO 4 buffer, pH 7.0, 172 5mM MgCl 2 (PBB). The cells were resuspended in PBB and the OD 600 was adjusted to 0.8. The 173 cell suspension was used immediately without the further addition of an energy source. To Outer membrane integrity assay. HN1157 was grown in modified LB broth + 5 mM MgSO 4 , 184 diluted 500-fold in LB, and incubated at 30 °C with shaking until the OD600 reached 0.65. The 185 cells were harvested, washed twice (50 mM potassium phosphate buffer, pH 7.0), and 186 resuspended in the same buffer at an OD 600 of 0.65. The cell suspension was transferred to the 187 wells of an assay plate containing compound or solvent, nitrocefin was added at final 188 concentration of 75 µM, OD 486 was measured over 20 min, and the velocity of hydrolysis (V h ) 189 was calculated. 190
Cytotoxicity assay. The cytotoxicity of MBX2319 against a mammalian cell line (HeLa, ATCC 191 CCL-2) was determined as described (37). The compound concentration that inhibits the 192 conversion of vital stain MTT to formazan by 50% (CC 50 ), as compared to an untreated control, 193 was determined using the 4-parameter curve-fitting program contained in GraphPad Prism, 194 version 5.04 (http://www.graphpad.com/). The assay was performed in triplicate in at least two 195 separate experiments. 196
RESULTS. 197
Identification of MBX2319. To identify compounds that act synergistically with ciprofloxacin 198 (CIP), we developed a cell-based reporter assay that reports on both SOS induction and 199 viability. Using the cell-based reporter assay, we screened 183,400 compounds, and identified 200 1,782 primary hits, which were evaluated in a panel of secondary assays for prioritization based 201 on potency and specificity. The details of the screening and secondary assays will be published 202 elsewhere. Based on the results of these analyses, MBX2319 ( Fig. 1 ) was chosen for further 203 study. 204
MBX2319 potentiates the antibacterial activity of fluoroquinolone and β-lactam antibiotics 205
against E. coli. We utilized a checkerboard assay to determine whether MBX2319 potentiates 206 the activity of two fluoroquinolones, ciprofloxacin (CIP) and levofloxacin (LEV), and a β-lactam, 207 piperacillin (PIP), against E. coli AB1157. The results, shown in Table 2 , demonstrate that 208 MBX2319 at 12.5 µM decreases the MICs of CIP, LEV, and PIP by 2, 4, and 8-fold, 209 respectively. MBX2319 alone did not exhibit antibacterial activity (MIC ≥100 µM). In addition, 210 MBX2319 increased the bactericidal activity of 0.016 µg/ml CIP (1× MIC), which is minimally 211 bactericidal against E. coli AB1157, in a dose-dependent manner ( Fig. 2A ). The highest 212 concentration of MBX2319 (3.13 µM) decreased viability (CFU/ml) by 10,000 fold after 4 h 213 exposure, as compared to 1× MIC CIP alone. In contrast, MBX2319 alone at concentrations up 214 to 50 µM did not affect growth. As a comparison, we measured the effect of various 215 concentrations of phenyl-arginine-β-naphthylamide (PAβN), a known EPI (13), in combination 216 with 0.016 µg/ml CIP in the time kill assay. The results of the assay are shown in Fig. 2B , and 217 demonstrate that PAβN at concentrations as high as 100 µM did not increase the bactericidal 218 activity of 0.016 µg/ml CIP. This finding is consistent with a previous report that showed that PAβN at a concentration of 25 mg/ml (48 µM) had a limited effect on the antibacterial of 220 fluoroquinolones against Enterobacteriaceae (38). 221 MBX2319 is an efflux pump inhibitor (EPI). To verify that the mechanism by which MBX2319 222 potentiates the antibacterial activity of fluoroquinolones and β-lactams is through inhibition of 223 efflux, we determined whether MBX2319 potentiated the antibacterial activity of CIP, LEV, and 224 PIP against a panel of efflux-defective mutants of E. coli AB1157. We reasoned that the 225 antibiotic sensitivity of mutants lacking the target of MBX2319 would not be affected by the 226 compound. The results of a checkerboard assay, shown in Table 2 , demonstrate that the MICs 227 for the ∆tolC and ∆acrB mutants were not affected by MBX2319, whereas, mutants defective in 228 other pumps that interact with TolC, such as AcrF (Table 2) , MacB, and EmrB (data not shown) 229 exhibited MIC shifts similar to those of WT (AB1157). Similarly, MBX2319 potentiated the 230 bactericidal activity of CIP against the ∆acrF strain, but not against ∆tolC and ∆acrB strains ( Fig  231   2C ). Finally, MBX2319 potentiated the antibacterial activity of CIP, LEV, and PIP by 4-8 fold 232 against E. coli strains 285 and 287 (Table 2) , which are CIP R mutants of E. coli AB1157 that 233 were selected during a serial passage in subinhibitory concentrations of CIP, and exhibit 234 increased efflux activity (see supplementary material). Significantly, MBX2319 reduced the 235
MICs against E. coli strains 285 and 287 to levels that are comparable to those obtained against 236 isogenic efflux-defective mutants (∆tolC). These findings indicate that the AcrAB-TolC efflux 237 pump, which is the major efflux pump in E. coli (39), is a target of MBX2319. However, because 238 deletion mutations of acrF, acrD, macB and emrB do not affect susceptibility to the antibiotics 239 used in this study, our results do not rule out the possibility that MBX2319 also inhibits the efflux 240 pumps encoded by these genes. 241
To confirm MBX2319 directly inhibits efflux, we used an assay that measures the accumulation 242 of the fluorescent DNA-binding dye Hoechst 33342 (H33342), which is a substrate of the AcrAB-243
TolC pump, in E. coli AB1157 (34). This assay has been used to estimate efflux activity in E. coli and S. enterica (34). When H33342 enters the cell it binds to the DNA minor groove, 245 becomes fluorescent, and can be detected using a fluorescent plate reader (Ex355, Em460). 246
Efflux-competent cells extrude H33342 and accumulate the dye at a relatively slow rate, 247 resulting in low levels of fluorescence. Conversely, efflux-defective cells accumulate 248 intracellular levels of H33342 at a higher rate, resulting in increased levels of fluorescence. The 249 results of the H33342 accumulation assay are shown in Fig 3A at concentrations ranging from 0.2 to 10 µM had no effect on the efflux of nitrocefin, suggesting 274 that this compound does not directly affect AcrB function at this range of concentrations. A 275 representative result for an assay performed using 1 µM PAβN is shown in Fig. 4B . 276 MBX2319 potentiates multiple antibiotics and biocides. Efflux pump inhibitors are known to 277 increase the antibacterial activity of a diverse group of antibiotics and biocides. To test this 278 prediction, we measured the ability of MBX2319 to increase the susceptibility of E. coli AB1157 279 to a broad spectrum of antibiotics and biocides. The data, shown in Table 3 , demonstrate that 280 MBX2319 increased susceptibility to several known AcrAB-TolC substrates, such as CIP, LEV, 281 nalidixic acid, PIP, oxacillin, and chloramphenicol, but not to gentamicin and carbenicillin, which 282 are not substrates (40). In general, the MIC shifts produced by MBX2319 were lower than those 283 of the ∆acrB and ∆tolC strains, but were similar to those produced by PAβN for fluoroquinolone 284 and β-lactam antibiotics. Interestingly, the MIC shifts produced by PAβN for rifampicin and was 285 greater than that of the ∆acrB strain, suggesting an additional mechanism of action for PAβN. 286 MBX2319 does not perturb bacterial membranes. Because the AcrAB-TolC efflux pump utilizes 287 proton motive force (41), compounds that perturb the proton gradient across the cytoplasmic 288 membrane can inhibit efflux through an indirect mechanism. To determine whether MBX2319 289 perturbs the transmembrane proton gradient, we measured uptake and accumulation in the 290 presence of MBX2319 of 3 H-TMG by the LacY permease, which requires proton motive force 291 (42). The results are shown in Table 4 . MBX2319 did not significantly inhibit uptake and 292 accumulation of 3 H-TMG at concentrations up to ~20 µM and thus, does not inhibit efflux 293 indirectly by perturbing the proton gradient.
PAβN has been shown to affect the integrity of the outer membrane, which is predicted to 295 increase the rate of permeation of antibiotics into the periplasm (13). To determine whether 296 MBX2319 affects the permeability of the outer membrane, we measured the influx of nitrocefin 297 in a strain deficient in AcrAB (HN1159). The data, shown in Table S3 (supplementary material), 298 demonstrate that 20 µM MBX2319 does not increase the rate of nitrocefin influx, indicating no 299 effect on outer membrane permeability. 300
Spectrum of activity. To determine whether MBX2319 inhibits the AcrAB-TolC orthologs of 301
other Gram-negative pathogens, we measured the antibacterial activity of MBX2319 in 302 combination with several antibiotics using three assays. First, we measured the MICs of several 303 antibiotics, alone or in combination with MBX2319 or PAβN at a concentration of 25 µM against 304 several Gram-negative pathogens. The data are shown in Table 5 . MBX2319 increased 305 significantly the activity of CIP and LEV against the majority of the organisms tested, whereas, 306
PAβN (25 µM) did not significantly affect the MICs. MBX2319 and PAβN increased the activity 307 of PIP and CEF against the majority of organisms tested, however, MBX2319 was active 308 against more organisms than was PAβN. In addition, MBX2319 increased the activity of CIP 309 and LEV against E. coli 331, which is resistant to fluoroquinolones. MBX2319 was not effective 310
against Proteus mirabilis or any of the antibiotics tested (data not shown). Table S4 ) is 325 comprised of strains that were publicly available clinical isolates; however, none of the strains 326 was resistant to high levels of fluoroquinolones. Because the spectrum of activity includes the 327 pathogens that are prevalent in urinary tract infections (UTI), the E. coli panel included several 328 strains isolated from UTIs. MBX2319 decreased the MIC 50 and MIC 90 for LEV (the 329 concentration of LEV that inhibits growth of 50% and 90% of the strains, respectively) by four 330 fold ( Fig. 6 ). In contrast, MBX2319 did not have a significant effect on the MIC 50 or MIC 90 for 331 PIP, probably because ~20% of strains appeared to be resistant to PIP, as evidenced by the 332 plateau in the cumulative % susceptible at ~80%, which is likely to be the result of β-lactamase 333 expression. 334
Cytotoxicity. The cytotoxicity of MBX2319 against HeLa cells was determined as described 335 (37). The concentration of compound that reduced cell viability by 50%, or CC 50 , was 336 determined using a four parameter curve fitting algorithm (GraphPad Prism). The CC 50 for 337 MBX2319 against HeLa cells was ≥ 100 µM, however, it is possible that the apparent lack of 338 cytotoxicity is due, at least in part, to the relatively low aqueous solubility of this compound. 339
DISCUSSION. 340
In this report, we describe the preliminary in vitro characterization of MBX2319, a novel inhibitor 341 of the RND-class AcrAB-TolC efflux pump, which is the major efflux pump in E. coli and other 342
Enterobacteriaceae and plays a major role in the MDR phenotype of these pathogens (7) . Our 343 results demonstrate that MBX2319 exhibits the following characteristics of an EPI, as described 344 Inhibits the extrusion or accumulation of AcrAB-TolC substrates, and 5) Does not affect the 348 energy source of AcrAB-TolC (proton gradient). 349
The most likely mechanism of inhibition of MBX2319 is through competitive inhibition and/or by The G-loop is predicted to move substrates to the distal binding pocket through peristaltic 360 action. Mutations that are predicted to prevent movement of the loop (G614P+G621P and 361 G616P+G619P) abolished efflux of doxorubicin and increased the sensitivity of the mutant 362 strain to erythromycin (47). Therefore, efflux pump inhibitors could inhibit the efflux of diverse 363 substrates by AcrB through binding to the G-loop. However, differences in the spectrum of 364 compounds potentiated by MBX2319 as compared to PAβN suggest that MBX2319 binds to a 365 different site in the AcrB binding pocket. Experiments that will further define the mechanism of 366 MBX2319 are underway in our laboratories. 367
The pyranopyridine MBX2319 appears to be a novel EPI, as it is not similar structurally to any of 368 the EPIs that have been described previously. However, a comparison of the structures of (29), reveals that these potent EPIs contain at least two hydrophobic ring systems that 371 presumably interact with hydrophobic residues in the substrate binding site. The activity 372 exhibited by MBX2319 in in vitro assays was comparable or superior to that of PAβN at the 373 same concentrations. Unlike PAβN, the activity of MBX2319 was not dependent on the 374 presence of primary amines, which were required for activity and were responsible for the 375 toxicity of PAβN and later analogs (23). The mechanism of action of MBX2319 appears to be 376 through the exclusive inhibition of AcrAB-TolC, as compared to PAβN, which also increases the 377 permeability of the outer membrane (13). This additional mechanism was apparent in the 378 potentiation of rifampicin to levels that are greater than those of an ∆acrB strain (see Table 3 ). 20* 3 9.9 ± 0.3 92 *compound was slightly above the solubility limit in assay buffer 617 618 619 
